James S. Zebrack

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 3K citations · Full text

Medicine, Endocrinology, Pharmacology +14

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 629 citations · Full text

Medicine, Endocrinology, Nephrology +15

The Changing Landscape for Stroke Prevention in AF

Menno V. Huisman, Kenneth J. Rothman, Miney Paquette et al. · Journal of the American College of Cardiology · 2017 · 281 citations · Full text

Medicine, Cardiology, Pharmacotherapy +10

C-reactive protein and angiographic coronary artery disease: independent and additive predictors of risk in subjects with angina

James S. Zebrack, Joseph B. Muhlestein, Benjamin D. Horne et al. · Journal of the American College of Cardiology · 2002 · 218 citations

Medicine, Cardiology, Clinical Sciences +16

Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial

Deepak L. Bhatt, Philippe Gabríel Steg, Shamir R Mehta et al. · The Lancet · 2019 · 210 citations · Full text

Medicine, Cardiology, Pharmacotherapy +15